Abstracts Archive - Page 2482 of 2605 - ACR Meeting Abstracts

Abstract Number: 1811 • 2012 ACR/ARHP Annual Meeting
On the Origin of the Type I Interferon Signature in Rheumatoid Arthritis
T.D. de Jong¹, Saskia Vosslamber¹, Maija-Leena Eloranta², Lars Rönnblom², Kyra Gelderman¹, Mary von Blomberg¹, Irene Bultink³, Alexandre Voskuyl⁴ and Cornelis L. Verweij¹, ¹Pathology, VU University Medical Center, Amsterdam, Netherlands, ²Department of Medical Sciences, Section of Rheumatology, Uppsala University, Uppsala, Sweden, ³Department of Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁴Rheumatology, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: Presence of a type I interferon (IFN) signature has been described for several autoimmune diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).…
Abstract Number: 1812 • 2012 ACR/ARHP Annual Meeting
A Retrospective Evaluation of the Clinical and Economic Implications of Gout in Nursing Home Residents in Hawaii Treated with Allopurinol
Joy Higa¹, Gregory Reardon² and Gregory Tong³, ¹Long Term Care Research Center, Kaneohe, HI, ²Informagenics, LLC, Worthington, OH, ³Takeda Pharmaceuticals America, Inc., Deerfield, IL
Background/Purpose: We describe patient characteristics, serum uric acid (sUA) levels while on allopurinol, and activities of daily living (ADL) in nursing home residents with gout.…
Abstract Number: 1813 • 2012 ACR/ARHP Annual Meeting
Accuracy of Veterans Affairs Database for Gout-Related Health Care Utilization
Jasvinder A. Singh, Department of Medicine, University of Alabama, Tuscaloosa, AL
Background/Purpose: Gout outcome studies have used administrative and claims databases. It is unknown whether administrative-derived data are accurate for gout-related utilization. The goal of the…
Abstract Number: 1814 • 2012 ACR/ARHP Annual Meeting
Comparing Clinical Characteristics and Comorbidities of Gout Patients Treated with Allopurinol or Febuxostat
Michael A. Becker¹, Xiangyang Ye², Kasem S. Akhras³, Rima H. Tawk⁴, Sudhir Unni², Jason Young² and Carl V. Asche⁵, ¹Medicine, University of Chicago, Chicago, IL, ²University of Utah College of Pharmacy, Salt Lake City, UT, ³Global Outcomes Research, Takeda Pharmaceuticals International, Inc., Deerfield, IL, ⁴Center for pharmacoeconomic Research, University of Illinois at Chicago, Chicago, IL, ⁵Center for Outcomes Research, University of Illinois College of Medicine at Peoria, Peoria, IL
Background/Purpose: Gout is a common acute and potentially progressive disease affecting approximately 8 million Americans. Hyperuricemia (serum urate levels [sUA] >6.8mg/dL) is a major pathogenic…
Abstract Number: 1815 • 2012 ACR/ARHP Annual Meeting
Factors Associated with a Prolonged Hospital Length of Stay for Patients with Acute Gout
Rebecca Sharim¹, Meghan Musselman² and Marissa Blum³, ¹Department of Medicine, Temple University Hospital, Philadelphia, PA, ²Temple University School of Medicine, Philadelphia, PA, ³Medicine/Rheumatology, Temple University School of Medicine, Philadelphia, PA
Background/Purpose: Management of gout in the hospital setting has been poor. This study aimed to describe patient characteristics and the treatment patterns of acute gout…
Abstract Number: 1816 • 2012 ACR/ARHP Annual Meeting
Relationship Between Race, Uric Acid Levels, Urate-Lowering Therapy and Resource Use in Patients with Gout
Kim Coley¹, Melissa Saul² and Karen Pater¹, ¹Pharmacy & Therapeutics, University of Pittsburgh, Pittsburgh, PA, ²Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Gout is a chronic inflammatory disease caused by the deposition of monosodium urate crystals in joints and soft tissues. The overall prevalence is increasing…
Abstract Number: 1817 • 2012 ACR/ARHP Annual Meeting
The Role of Repeating Tuberculin Skin Tests During Biologic Therapy
Joseph R. Lutt¹ and Kevin L. Winthrop², ¹Colorado Center for Arthritis & Osteoporosis, Boulder, CO, ²Dept of Infectious Disease, Oregon Health & Science University, Portland, OR
The Role of Repeating Tuberculin Skin Tests during Biologic TherapyBackground/Purpose: Prior to starting biologic therapy, it is recommended that all patients be screened for tuberculosis…
Abstract Number: 1818 • 2012 ACR/ARHP Annual Meeting
Latent Tuberculosis Detection and Tuberculosis Reactivation in Patients Receiving Anti-TNFá Drugs: A Nationwide Italian Survey
Fabrizio Cantini¹, Ennio Lubrano², Alessandro Mathieu³, Antonio Marchesoni⁴, Carlo Salvarani⁵, Raffaele Scarpa⁶ and Antonio Spadaro⁷, ¹U.O.C. Reumatologia, Prato Hospital, Prato, Italy, ²Cattedra di Reumatologia, Università del Molise, Campobasso, Italy, ³Unit and Chair of Rheumatology, University Hospital of Cagliari, Cagliari, Italy, ⁴Rheumatology, Istituto Ortopedico Gaetano Pini, Milano, Italy, ⁵Rheumatology, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy, ⁶c/o Medical University, Via Pansini 5, Naples, Italy, ⁷Cattedra di Reumatologia, Univeristà La Sapienza di Roma, Roma, Italy
Background/Purpose: Anti-TNFα drugs are associated with an increased risk of tuberculosis (TB) and several recommendation sets for latent tubercular infection (LTBI) detection and TB reactivation…
Abstract Number: 1778 • 2012 ACR/ARHP Annual Meeting
Adenosine A2A Receptor (A_2AR) Activation Stimulates Increased Expression of Collagen-1 and Collagen-3 by Different Signaling Pathways in Normal Human Dermal Fibroblasts
Miguel Perez Aso¹ and Bruce N. Cronstein², ¹NYU Univ Medical Center, New York, NY, ²Internal Medicine, NYU School of Medicine, Division of Rheumatology, New York, NY
Background/Purpose: Pathological fibrosis in the skin and other organs is the hallmark of scleroderma and other fibrosing diseases. Adenosine, acting at A2AR, plays a critical…
Abstract Number: 1779 • 2012 ACR/ARHP Annual Meeting
The Loss of Syndecan-4 Aggravates Inflammatory Colitis in Mice
Athanasios Stratis¹, Dominik Bettenworth², Mareike Fröhling¹, Peter Paruzel¹, Adelheid Korb-Pap¹, Corinna Wehmeyer¹, Berno Dankbar¹, Frank Echtermeyer³, Andreas Lügering⁴ and Thomas Pap¹, ¹Institute of Experimental Musculoskeletal Medicine (IEMM), University Hospital Muenster, Muenster, Germany, ²Department of Medicine B University Hospital Münster, University Hospital Muenster, Muenster, Germany, ³Dept. of Anaesthesiology and Intensive Care Medicine, University Hospital Hannover, Hanover, Germany, ⁴Department of Medicine B University of Münster, MVZ Portal 10, Münster, University Hospital Muenster, Muenster, Germany
Background/Purpose: Syndecan-4 (sdc4) is a transmembrane heparan sulfate proteoglycan. Several studies have implicated sdc4 in cell-matrix adhesion, cell migration, differentiation, proliferation and play an important…
Abstract Number: 1780 • 2012 ACR/ARHP Annual Meeting
Association Between Chondrocyte Hypertrophy and Angiogenesis of Cartilage in Osteoarthritis
Laurence Pesesse¹, Christelle Sanchez², Jean-Pierre Delcour³, Caroline Baudouin⁴, Philippe Msika⁴ and Yves Henrotin⁵, ¹Bone and Cartilage Research Unit, University of Liège, Liège, Belgium, ²Bone and Cartilage Research Unit, University of Liège, Liege, Belgium, ³Orthopedic surgery, Centre hospitalier du Bois de l'Abbaye, Seraing, Belgium, ⁴IRD Direction, Laboratoires Expanscience, Epernon, France, ⁵University of Liège, Bone and Cartilage Research Unit, Liège, Belgium
Background/Purpose: Chondrocyte hypertrophy is commonly observed in OA cartilage, associated with matrix mineralization and vascularization. In our previous work, we demonstrated that hypertrophic differentiation of…
Abstract Number: 1781 • 2012 ACR/ARHP Annual Meeting
Functional Analysis of the Primary Cilium in Rheumatoid Arthritis Synovial Fibroblasts
Kerstin Klein¹, Beat A. Michel¹, Alexander Vogetseder², Renate Gay¹, Steffen Gay¹ and Caroline Ospelt¹, ¹Center of Experimental Rheumatology, University Hospital Zurich and Zurich Center of Integrative Human Physiology (ZIHP), Zurich, Switzerland, ²Department of Pathology, Department of Pathology, University Hospital Zurich, Zurich, Switzerland
Background/Purpose: The primary cilium is a microtubule-based, polarized, antenna structure that emanates from the cell surface of most mammalian cell types. It serves as a…
Abstract Number: 1782 • 2012 ACR/ARHP Annual Meeting
Dual Effects of Soluble FasL and Membrane Bound FasL On Fibroblast-Like Synoviocytes Cells (FLS) From Rheumatoid Arthritis (RA) Patients
Rachel Audo¹, Flavia Calmon-Hamaty¹, Bernard Combe², Michael Hahne¹ and Jacques Morel³, ¹IGMM, CNRS UMR5535, Montpellier, Montpellier, France, ²Rheumatology, Hopital Lapeyronie, Montpellier, France, ³Dpartment of Rheumatology, Lapeyronie Hospital, Montpellier, France
Background/Purpose: Membrane bound FasL (mFasL) is able to induce fibroblast-like synoviocytes (FLS) cell death. In experimental arthritis mouse models, injection of agonistic antibody (Ab) anti-Fas…
Abstract Number: 1783 • 2012 ACR/ARHP Annual Meeting
TNFα Influences RasGRP1 and RasGRP3 Expression Levels in PBMC, B and T Cells
Marie-Laure Potier¹, Martine Hiron¹, Clément Guillou¹, Céline Derambure², Olivier Boyer³, Xavier Le Loët⁴, Olivier Vittecoq⁵ and Thierry Lequerré⁶, ¹Inserm 905 & Institute for Biomedical Research, University of Rouen, Rouen, France, ²Inserm 905 & Institute for Biomedical Research, University of Rouen, Rouen, France, Rouen, France, ³Immunology, Inserm 905, Institute for Biomedical research, University of Rouen, Rouen, France, ⁴Rheumatology Department, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen Cedex, France, ⁵Rheumatology, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen Cedex, France, ⁶Rheumatology Department & Inserm 905, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen Cedex, France
Background/Purpose: Rheumatoid arthritis (RA) is the most common inflammatory arthritis. B and T lymphocytes play a central role in the pathophysiology of RA. RasGRP is…
Abstract Number: 1784 • 2012 ACR/ARHP Annual Meeting
Dual Function of Interleukin-33 in Fibroblast-Like Synoviocytes in Patients with Rheumatoid Arthritis
Min W. So¹, Bon S. Koo¹, You J. Kim¹, You-G Kim¹, Wook J. Seo², Chang-K Lee¹ and Bin Yoo¹, ¹Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, ²Internal Medicine, Seoul Veterans Hospital, Seoul, South Korea
Background/Purpose: IL-33 is a new member of the IL-1 cytokine family. Recent studies in an animal model of murine collagen-induced arthritis and human rheumatoid arthritis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].